NBIX Neurocrine Biosciencesdata gap · 80% coverage
Health Care · Biotechnology · close $135.71 (2026-10-16) · latest quarter in EDGAR: 2026-06-30
Neurocrine Biosciences (NBIX) has a ThetaGrade House Rating of 74/100 (grade B), ranking #59 of 150 in Health Care. Its strongest pillars are cash flow (85) and profitability (79); its weakest is balance sheet (64). Data gap: 4 factors without usable data, so 80% of the method weight is covered. TTM revenue growth is 34.4% and operating margin 23.6%.
Data as of .
Data gap
No usable data for: Consensus score (1–5), 90-day net rating shift, 4Q gross-margin change, Interest coverage. Data gap: no usable data for this factor, so it is left out and its weight is shared among the factors that do have data (no value is imputed). 80% of the full method weight is backed by data.
Analyst sentiment
weight 7.5% · no data · —| Consensus score (1–5) (0.0%)data gap | derived | — |
| 90-day net rating shift (0.0%)data gap | derived | — |
Growth
weight 30.83% (→33.3%) · 76| Revenue growth YoY (TTM) (13.3%) | 34.4% | 82 |
| EPS growth YoY (TTM) (13.3%) | 102.1% | 91 |
| Revenue acceleration (6.7%) | -2.8% | 32 |
Profitability
weight 18.5% (→20.0%) · 79| Operating margin (20.0%) | 23.6% | 79 |
| 4Q gross-margin change (0.0%)data gap | — | — |
Balance sheet
weight 18.5% (→20.0%) · 64| Net debt / EBITDA (13.3%) | -0.40× | 76 |
| Current ratio (6.7%) | 1.87 | 41 |
| Interest coverage (0.0%)data gap | — | — |
Cash flow
weight 12.33% (→13.3%) · 85| FCF margin (6.7%) | 26.2% | 86 |
| FCF yield (6.7%) | 5.4% | 83 |
Valuation
weight 12.33% (→13.3%) · 69| P/E (inverted) (6.7%) | 19.87× | 79 |
| EV/Sales (inverted) (6.7%) | 3.99× | 59 |
Technicals (EOD)
| RSI(14) | 34.6 |
| EMA 9 / 21 | 138.64 / 141.93 |
| 200-day SMA | 147.04 |
| Volume vs 20d avg | 0.75× |
| 20-day return | -10.6% |
Exit-rule monitor
- WATCHTrend: close below 200-day average
Data source per metric (SEC XBRL tag or derivation): Revenue: RevenueFromContractWithCustomerExcludingAssessedTax · Operating income: OperatingIncomeLoss · D&A: Depreciation · EPS: EarningsPerShareDiluted · Market cap: SEC shares (dei EntityCommonStockSharesOutstanding (cover page)) × EOD close · P/E: EOD close ÷ SEC TTM EPS (EarningsPerShareDiluted).
Get rating changes like NBIX's in the free Daily Brief
The market’s key events and signals, digested before the open.
- ✓ Pre-market Daily Brief: events, headlines, rating changes (2-min read)
- ✓ Sunday: Top 5 Weekly Picks, exit alerts, CSP put watchlist
- ✓ OPEX, FOMC, CPI and jobs-day reminders
Free. Want more? See Premium (waitlist).
FAQ
- What is NBIX's House Rating?
- NBIX scores 74 out of 100 (grade B) as of 2026-10-16, ranking #59 of 150 Health Care stocks we cover.
- What do analysts say about NBIX?
- We do not have enough analyst-sentiment data to score this stock.
- When does NBIX report earnings next?
- NBIX's next earnings report is estimated for about 2026-10-27 (window 2026-10-21 to 2026-11-02), based on its past SEC 8-K earnings filings. This is an estimate, not a company-confirmed date.
- Is NBIX a buy?
- ThetaGrade does not give personal advice. The House Rating is an educational, rules-based summary of public data; see the methodology for how it is built.
Sources: SEC EDGAR filings (fetched 2026-10-18), Finnhub recommendation trends, Massive EOD prices. Scores are sector percentiles; a factor without usable data is a data gap: it is left out and the remaining weights are renormalized (nothing is imputed). Educational only. Methodology